INCY Incyte Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: INCY

Price (delayed)

$70.81

Market cap

$15.79B

P/E Ratio

46.28

Dividend/share

N/A

EPS

$1.53

Enterprise value

$12.87B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug, ...

Highlights
INCY's equity is up by 16% year-on-year and by 3.4% since the previous quarter
Incyte's revenue has increased by 14% YoY
INCY's P/E is 75% above its last 4 quarters average of 26.5
INCY's EPS has shrunk by 64% YoY and by 61% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.incyte.com/
Peers: AMGN LGND LLY PFE

Key stats

What are the main financial stats of INCY
Market
Shares outstanding
222.97M
Market cap
$15.79B
Enterprise value
$12.87B
Valuations
Price to earnings (P/E)
46.28
Price to book (P/B)
3.6
Price to sales (P/S)
4.63
EV/EBIT
24.2
EV/EBITDA
21.46
EV/Sales
3.79
Earnings
Revenue
$3.39B
EBIT
$531.78M
EBITDA
$599.64M
Free cash flow
$892.11M
Per share
EPS
$1.53
Free cash flow per share
$4.02
Book value per share
$19.64
Revenue per share
$15.29
TBVPS
$25.03
Balance sheet
Total assets
$5.84B
Total liabilities
$1.47B
Debt
$33.26M
Equity
$4.37B
Working capital
$2.94B
Liquidity
Debt to equity
0.01
Current ratio
3.54
Quick ratio
3.36
Net debt/EBITDA
-4.87
Margins
EBITDA margin
17.7%
Gross margin
93.9%
Net margin
10%
Operating margin
17.1%
Efficiency
Return on assets
6.3%
Return on equity
8.2%
Return on invested capital
33.4%
Return on capital employed
11.4%
Return on sales
15.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INCY stock price

How has the Incyte stock price performed over time
Intraday
0.83%
1 week
-4.59%
1 month
-7.57%
1 year
-9.75%
YTD
-11.84%
QTD
-11.84%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$3.39B
Gross profit
$3.19B
Operating income
$579.44M
Net income
$340.66M
Gross margin
93.9%
Net margin
10%
The net margin has dropped by 69% year-on-year and by 62% since the previous quarter
INCY's net income has dropped by 64% year-on-year and by 61% since the previous quarter
Incyte's revenue has increased by 14% YoY
INCY's operating margin is down by 13% year-on-year and by 10% since the previous quarter

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
P/E
46.28
P/B
3.6
P/S
4.63
EV/EBIT
24.2
EV/EBITDA
21.46
EV/Sales
3.79
INCY's P/E is 75% above its last 4 quarters average of 26.5
INCY's EPS has shrunk by 64% YoY and by 61% QoQ
The stock's price to book (P/B) is 47% less than its 5-year quarterly average of 6.8 and 12% less than its last 4 quarters average of 4.1
INCY's equity is up by 16% year-on-year and by 3.4% since the previous quarter
INCY's P/S is 37% below its 5-year quarterly average of 7.3 and 9% below its last 4 quarters average of 5.1
Incyte's revenue has increased by 14% YoY

Efficiency

How efficient is Incyte business performance
The ROE has plunged by 73% YoY and by 63% from the previous quarter
INCY's return on assets has dropped by 72% year-on-year and by 63% since the previous quarter
The ROIC has decreased by 25% YoY and by 2.9% from the previous quarter
INCY's ROS is down by 18% YoY and by 9% QoQ

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
INCY's total liabilities is up by 26% year-on-year and by 15% since the previous quarter
Incyte's total assets has increased by 18% YoY and by 6% from the previous quarter
The debt is 99% smaller than the equity
INCY's equity is up by 16% year-on-year and by 3.4% since the previous quarter
The debt is down by 2.9% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.